SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A powerful rally has pushed AMD to record highs and past the $1 trillion market-cap milestone for the first time, with bulls citing reports of upcoming chip price increases, strengthening server-CPU demand, and warrant milestones tied to OpenAI and Meta deals. Bears view the move as an overextended, high-multiple rally inflated by short covering, with many traders taking profits or opening shorts rather than chasing.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is surging on a CPU-demand narrative, with traders citing the rapid adoption of Meta's Muse AI agent as fueling expectations that agentic AI workloads will drive processor demand  a move also lifting Arm and AMD. Bulls cheer short-covering speculation and big options gains, pointing to the CEO's remarks that Intel can meet only about half of customer CPU demand and hopes for an SK Hynix memory partnership at its Ohio fabs, while skeptics call the stock overextended for a still-unprofitable company and expect profit-taking.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is sliding after its Capital Markets Day, where long-term pipeline targets and guidance for only peer-level revenue growth through 2030 failed to ease concerns about Eli Lilly competition and the looming semaglutide patent cliff. The community is split between bulls calling the selloff an overreaction on an undervalued stock and bears criticizing CEO Mike Doustdar's communication and the subdued growth outlook.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals is surging after President Trump announced a U.S.-Denmark security agreement granting the U.S. permanent security access to Greenland, which bulls see as de-risking the company's Tanbreez rare earth project, alongside heavy speculation about a short squeeze given elevated short interest. Skeptics counter that the deal does not transfer mining rights, the company remains pre-revenue, and the move is a geopolitical headline rather than a change to fundamentals.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

A rapid series of enterprise AI contract announcements  AI compute capacity leases and prepaid token-based API agreements of escalating size  is dominating the discussion, with bulls framing the deal flow as a shift from one-off projects toward recurring, subscription-style revenue while skeptics note the stock isn't reflecting the news and question whether contracts will convert into recognized revenue, margins, and cash. Conversation also centers heavily on the company's AI security white paper for its Lingyan Miaoyu LLM, which many traders cite as a credibility step toward enterprise adoption.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Reports that Paramount is in advanced settlement talks with California's attorney general to resolve the state-led antitrust suit blocking its Warner Bros. Discovery merger are driving attention, with discussed terms reportedly including a major California production investment, film-release commitments, and CNN editorial safeguards. Many traders view the talks as clearing a path for the deal to close, while others denounce the potential concessions as a political shakedown and argue Paramount should reject them or relocate rather than settle.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq-100 rally toward record territory is dominating the conversation, with traders citing sliding crude oil on hopes of U.S.-Iran de-escalation, easing Treasury yields, and AI/semiconductor strength as drivers, while many question what news is behind the move given the Fed's hawkish rate hike, elevated yields, and record diesel prices. Reaction is split between call buyers celebrating a melt-up toward new highs and skeptics calling it an unsustainable, manipulated-looking pump or bull trap, with some traders speculating the run is election-driven ahead of the Trump-Xi summit.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

The leveraged bear ETF is sliding sharply as semiconductor stocks, led by memory names, rally and break through resistance, trapping inverse traders who are averaging down on bets the AI-driven chip rally is a bubble. Debate pits bears citing hawkish Fed rate-hike expectations and AI-slowdown warnings against skeptics pointing to the sector's breakout strength and the ETF's built-in decay.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD shares have surged to a 52-week high as reports indicate Paramount Skydance is in advanced settlement talks with California's attorney general over the state-led antitrust suit blocking their merger, with a proposed California production investment and concessions such as film-release commitments and CNN editorial safeguards reportedly under discussion. Traders are largely bullish on the deal's progress and the narrowing gap to the agreed acquisition price, though some remain skeptical of conflicting reports and caution that no final settlement has been confirmed.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm is rallying alongside AMD and Intel as a trader-driven CPU-demand narrativeagentic AI shifting momentum from memory to data-center CPUsgains steam, amplified by CEO Rene Haas's televised comments expressing confidence in converting strong AGI CPU demand into revenue and dismissing AI-threat concerns as sensational. Community reaction is euphoric, with heavy call-buying and breakout celebration, though valuation-focused bears argue the move is detached from fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Full Transcript: Sanofi Q2 2026 Earnings Call

Sanofi (NASDAQ:SNY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.
Benzinga APIs provide real-time access to earningsread more...

Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?

Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.

Sanofi To Receive 26.4% Stake In Cheplapharm For Mature Medicines

(RTTNews) - Sanofi (SNY, SAN.PA), a healthcare company, on Monday announced an agreement with Cheplapharm to create a strategic partnership for its mature medicines portfolio...

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.

Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.

NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open  

Equity

Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.

FDA Approves 3 New COVID-19 Vaccines

FDA Approves 3 New COVID-19 Vaccines

 Authored by Zachary Stieber via The Epoch Times,

The Food and Drug Administration on Aug. 27 approved COVID-19 vaccines from Pfizer, Moderna, and Sanofi.
A nurse prepares to give a COVID-19 vaccine to a child in Denver, Colo., on Nov. 3, 2021...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$42.69
Prev Close	$42.48
Open	$42.66
Dividend Yield	3.64%
50-Day Moving Average	$43.90
Beta	0.30
Avg. Volume	2.44M
PE Ratio	21.79

52-Week High	$52.68
52-Week Low	$40.89
Market Capitalization	$101.25B
EPS (Annual)	$2.41
Price to Book	1.30
Revenue Per Employee	$643,658.13

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNY Fundamentals